Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden – a feasibility study

1. Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism 2018; 80: 80–90. doi: 10.1016/j.metabol.2017.11.012 TerposE ChristoulasD GavriatopoulouM Biology and treatment of myeloma related bone disease Metabolism 2018 80 80 90 10.1016/j.metabol.2017.11.012 Open DOISearch in Google Scholar

2. Hansford BG, Silbermann R. Advanced imaging of multiple myeloma bone disease. Front Endocrinol 2018; 9: 436. doi: 10.3389/fendo.2018.00436 HansfordBG SilbermannR Advanced imaging of multiple myeloma bone disease Front Endocrinol 2018 9 436 10.3389/fendo.2018.00436 Open DOISearch in Google Scholar

3. Duvauferrier R, Valence M, Patrat-Delon S, Brillet E, Niederberger E, Marchand A, et al. Current role of CT and whole body MRI in multiple myeloma. Diagn Interv Imaging 2013; 94: 169–83. doi: 10.1016/j.diii.2012.12.001 DuvauferrierR ValenceM Patrat-DelonS BrilletE NiederbergerE MarchandA Current role of CT and whole body MRI in multiple myeloma Diagn Interv Imaging 2013 94 169 83 10.1016/j.diii.2012.12.001 Open DOISearch in Google Scholar

4. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545–56. doi: 10.1038/leu.2009.89 DimopoulosM TerposE ComenzoRL TosiP BeksacM SezerO International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma Leukemia 2009 23 1545 56 10.1038/leu.2009.89 Open DOISearch in Google Scholar

5. Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005; 16:1824–8. doi: 10.1093/annonc/mdi362 MoulopoulosLA GikaD AnagnostopoulosA DelasalleK WeberD AlexanianR Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma Ann Oncol 2005 16 1824 8 10.1093/annonc/mdi362 Open DOISearch in Google Scholar

6. Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 2019; 291: 5–13. doi: 10.1148/radiol.2019181949 MessiouC HillengassJ DelormeS LecouvetFE MoulopoulosLA CollinsDJ Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: myeloma response assessment and diagnosis system (MY-RADS) Radiology 2019 291 5 13 10.1148/radiol.2019181949 Open DOISearch in Google Scholar

7. Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33: 657–64. doi: 10.1200/JCO.2014.57.9961 DimopoulosMA HillengassJ UsmaniS ZamagniE LentzschS DaviesFE Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement J Clin Oncol 2015 33 657 64 10.1200/JCO.2014.57.9961 Open DOISearch in Google Scholar

8. Messiou C, Kaiser M. Whole body diffusion weighted MRI – a new view of myeloma. Br J Haematol 2015; 171: 29–37. doi: 10.1111/bjh.13509 MessiouC KaiserM Whole body diffusion weighted MRI – a new view of myeloma Br J Haematol 2015 171 29 37 10.1111/bjh.13509 Open DOISearch in Google Scholar

9. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN Guidelines Insights: multiple myeloma, Version 3.2018. J Natl Compr Canc Netw 2018; 16: 11–20. doi: 10.6004/jnccn.2018.0002 KumarSK CallanderNS AlsinaM AtanackovicD BiermannJS CastilloJ NCCN Guidelines Insights: multiple myeloma, Version 3.2018 J Natl Compr Canc Netw 2018 16 11 20 10.6004/jnccn.2018.0002 Open DOISearch in Google Scholar

10. Dutoit JC, Verstraete KL. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging 2016; 7: 553–569. doi: 10.1007/s13244-016-0492-7 DutoitJC VerstraeteKL MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings Insights Imaging 2016 7 553 569 10.1007/s13244-016-0492-7 Open DOISearch in Google Scholar

11. Lecouvet FE, Vande Berg BC, Michaux L, Malghem J, Maldague BE, Jamart J, et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998; 209: 653–60. doi: 10.1148/radiology.209.3.9844655 LecouvetFE Vande BergBC MichauxL MalghemJ MaldagueBE JamartJ Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging Radiology 1998 209 653 60 10.1148/radiology.209.3.9844655 Open DOISearch in Google Scholar

12. Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005; 55: 56–63. doi: 10.1016/j.ejrad.2005.01.017 Baur-MelnykA BuhmannS DürrHR ReiserM Role of MRI for the diagnosis and prognosis of multiple myeloma Eur J Radiol 2005 55 56 63 10.1016/j.ejrad.2005.01.017 Open DOISearch in Google Scholar

13. Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992; 185: 833–40. doi: 10.1148/radiology.185.3.1438772 MoulopoulosLA VarmaDG DimopoulosMA LeedsNE KimEE JohnstonDA Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease Radiology 1992 185 833 40 10.1148/radiology.185.3.1438772 Open DOISearch in Google Scholar

14. Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol 2014; 24: 2754–65. doi: 10.1007/s00330-014-3324-5 DutoitJC VanderkerkenMA AnthonissenJ DochyF VerstraeteKL The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma Eur Radiol 2014 24 2754 65 10.1007/s00330-014-3324-5 Open DOISearch in Google Scholar

15. Padhani AR, van Ree K, Collins DJ, D’Sa S, Makris A. Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI. AJR Am J Roentgenol 2013; 200: 163–70. doi: 10.2214/AJR.11.8185 PadhaniAR van ReeK CollinsDJ D’SaS MakrisA Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI AJR Am J Roentgenol 2013 200 163 70 10.2214/AJR.11.8185 Open DOISearch in Google Scholar

16. Zhang Y, Xiong X, Fu Z, Dai H, Yao F, Liu D, et al. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study. Eur J Radiol 2019; 120: 108695. doi: 10.1016/j.ejrad.2019.108695 ZhangY XiongX FuZ DaiH YaoF LiuD Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study Eur J Radiol 2019 120 108695 10.1016/j.ejrad.2019.108695 Open DOISearch in Google Scholar

17. Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–84. doi: 10.1182/blood-2006-07-038430 ShaughnessyJDJr. ZhanF BuringtonBE HuangY CollaS HanamuraI A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Blood 2007 109 2276 84 10.1182/blood-2006-07-038430 Open DOISearch in Google Scholar

18. Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era. Hematol Rep 2017; 9: 6887. doi: 10.4081/hr.2017.6887 NakayaA FujitaS SatakeA NakanishiT AzumaY TsubokuraY Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era Hematol Rep 2017 9 6887 10.4081/hr.2017.6887 Open DOISearch in Google Scholar

19. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–8. doi: 10.1038/leu.2013.313 KumarSK DispenzieriA LacyMQ GertzMA BuadiFK PandeyS Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 2014 28 1122 8 10.1038/leu.2013.313 Open DOISearch in Google Scholar

20. Younes M, Hachfi H, Hammouda F, Younes K, Ben Hammouda S, Jguirim M, et al. [Survival prognosis factors in multiple myeloma]. [French]. Tunis Med 2014; 92: 399–405. PMID: 25741841 YounesM HachfiH HammoudaF YounesK Ben HammoudaS JguirimM [Survival prognosis factors in multiple myeloma]. [French] Tunis Med 2014 92 399 405 25741841 Search in Google Scholar

21. Yamasaki S, Kohno K, Kadowaki M, Takase K, Okamura S. Dose-adjusted lenalidomide combined with low-dose dexamethasone rescues older patients with bortezomib-resistant multiple myeloma. Intern Med 2015; 54: 1711–5. doi: 10.2169/internalmedicine.54.4075 YamasakiS KohnoK KadowakiM TakaseK OkamuraS Dose-adjusted lenalidomide combined with low-dose dexamethasone rescues older patients with bortezomib-resistant multiple myeloma Intern Med 2015 54 1711 5 10.2169/internalmedicine.54.4075 Open DOISearch in Google Scholar

22. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20. doi: 10.1200/JCO.2005.04.242 GreippPR San MiguelJ DurieBG CrowleyJJ BarlogieB BladéJ International staging system for multiple myeloma J Clin Oncol 2005 23 3412 20 10.1200/JCO.2005.04.242 Open DOISearch in Google Scholar

23. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863–9. doi: 10.1200/JCO.2015.61.2267 PalumboA Avet-LoiseauH OlivaS LokhorstHM GoldschmidtH RosinolL Revised international staging system for multiple myeloma: A report from International Myeloma Working Group J Clin Oncol 2015 33 2863 9 10.1200/JCO.2015.61.2267 Open DOISearch in Google Scholar

24. Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol 2011; 90: 423–8. doi: 10.1007/s00277-010-1130-y BarlogieB BolejackV SchellM CrowleyJ Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival Ann Hematol 2011 90 423 8 10.1007/s00277-010-1130-y Open DOISearch in Google Scholar

25. Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S. Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol 2008; 25: 154–60. doi: 10.1007/s12032-007-9011-5 ColovićM JankovićG SuvajdzićN MilićN DordevićV JankovićS Thirty patients with primary plasma cell leukemia: a single center experience Med Oncol 2008 25 154 60 10.1007/s12032-007-9011-5 Open DOISearch in Google Scholar

26. Perez-Andres M, Almeida J, Martin-Ayuso M, De Las Heras N, Moro MJ, Martin-Nuñez G, et al. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease. Int J Cancer 2009; 124: 367–75. doi: 10.1002/ijc.23941 Perez-AndresM AlmeidaJ Martin-AyusoM De Las HerasN MoroMJ Martin-NuñezG Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease Int J Cancer 2009 124 367 75 10.1002/ijc.23941 Open DOISearch in Google Scholar

27. Tian C, Wang L, Wu L, Zhu L, Xu W, Ye Z, et al. Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. Biosci Rep 2018; 38: BSR20171697. doi: 10.1042/BSR20171697 TianC WangL WuL ZhuL XuW YeZ Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis Biosci Rep 2018 38 BSR20171697 10.1042/BSR20171697 Open DOISearch in Google Scholar

28. Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002; 95: 1334–45. doi: 10.1002/cncr.10818 BaurA StäblerA NagelD LamerzR BartlR HillerE Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002 95 1334 45 10.1002/cncr.10818 Open DOISearch in Google Scholar

29. Baur A, Stäbler A, Bartl R, Lamerz R, Reiser M. [Infiltration patterns of plasmacytomas in magnetic resonance tomography]. Rofo 1996; 164: 457–63. doi: 10.1055/s-2007-1015689 BaurA StäblerA BartlR LamerzR ReiserM [Infiltration patterns of plasmacytomas in magnetic resonance tomography] Rofo 1996 164 457 63 10.1055/s-2007-1015689 Open DOISearch in Google Scholar